Supplementary Table 3. High conservation within cytotoxic T-cell epitopes despite potent ELISpot responses to HLA-B*14, -B*3501 and -B*5301-restricted epitopes in HIV-2-infected Caió participants. Sites where amino acid variations are present within autologous sequences are underlined. These epitopes represent 3 of the 4 known cytotoxic T-cell epitopes in the HIV-2 capsid [7]. Peptide ELISpot response Participant Autologous sequence used (SFU/106 PBMCs) 215 B14_1 DRFYKSLRA 1051 B14_2 DRFYKSLRA DRFYKSLRA 895 B14_3 DRFYKSLRA B14_4 1020 DRFYKSLRA 760 NPVPVGNIY B3501_1 350 NPVPVGNIY B3501_2 275 NPVPVGNIY B3501_3 NPVPVGNIY 1100 NPVPVGNIY B3501_4 1025 NPVPVGSIY B3501_5 2190 NPIPVGNIY B3501_6 155 NPVPVGSIY B3501_7 555 TPYDINQML B5301_1 B5301_2 20 TPYDINQML 840 TPYDINQML B5301_3 1130 TPYDINQML B5301_4 TPYDINQML 3210 TPYDINQML B5301_5 2245 TPYDINQML B5301_6 155 TPYDINQML B5301_7 1100 TPYDINQML B5301_8
Supplementary Table 3. High conservation within cytotoxic T-cell epitopes despite potent ELISpot responses to HLA-B*14, -B*3501 and -B*5301-restricted epitopes in HIV-2-infected Caió participants. Sites where amino acid variations are present within autologous sequences are underlined. These epitopes represent 3 of the 4 known cytotoxic T-cell epitopes in the HIV-2 capsid [7]. Participant Peptide used ELISpot response (SFU/106 PBMCs) Autologous sequence B14_1 DRFYKSLRA 215 DRFYKSLRA B14_2 1051 DRFYKSLRA B14_3 895 DRFYKSLRA B14_4 1020 DRFYKSLRA B3501_1 NPVPVGNIY 760 NPVPVGNIY B3501_2 350 NPVPVGNIY B3501_3 275 NPVPVGNIY B3501_4 1100 NPVPVGNIY B3501_5 1025 NPVPVGSIY B3501_6 2190 NPIPVGNIY B3501_7 155 NPVPVGSIY B5301_1 TPYDINQML 555 TPYDINQML B5301_2 20 TPYDINQML B5301_3 840 TPYDINQML B5301_4 1130 TPYDINQML B5301_5 3210 TPYDINQML B5301_6 2245 TPYDINQML B5301_7 155 TPYDINQML B5301_8 1100 TPYDINQML
QAD_2018_01_16_SILVA_AIDS-D-17-00886_SDC1.docx